What changed in Insulet Corporation's latest annual report
In the year ended 31 Dec 2025, Insulet Corporation's revenue rose 30.7% to USD 2.71bn, from USD 2.07bn; net income fell 40.9% to USD 247.10m, from USD 418.30m; shareholders' equity rose 25.1% to USD 1.52bn, from USD 1.21bn.
Year ended 31 Dec 2025. Source: 10-K filed 18 Feb 2026, read it on SEC EDGAR.
USD 2.07bn to USD 2.71bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.07bn | 2.71bn | Up 30.7% |
| Net income | 418.30m | 247.10m | Down 40.9% |
| Total assets | 3.09bn | 3.19bn | Up 3.3% |
| Total liabilities | 1.88bn | 1.68bn | Down 10.7% |
| Shareholders' equity | 1.21bn | 1.52bn | Up 25.1% |
Questions people ask
Did Insulet Corporation's revenue grow last year?
Revenue grew 30.7%, from USD 2.07bn to USD 2.71bn in the year ended 31 Dec 2025.
Is Insulet Corporation profitable?
Yes. Net income was USD 247.10m in the year ended 31 Dec 2025. The year before: USD 418.30m.
Where do these numbers come from?
From Insulet Corporation's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Insulet Corporation?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Surgical & Medical Instruments & Apparatus companies
- Stryker CorpLong-term debt up 21.9%
- 3M CompanyShareholders' equity up 22.4%
- Boston Scientific CorporationCash and cash equivalents up 374.6%
- Becton, Dickinson And CompanyCash and cash equivalents down 62.7%
- Medline Inc.Cash and cash equivalents up 874.4%
- ResMed Inc.Long-term debt down 39.3%
- Dexcom, Inc.Cash and cash equivalents up 51.4%
- West Pharmaceutical Services, Inc.Cash and cash equivalents up 63.3%